L-165041

L-165041 is a cell permeable PPARδ agonist, with Kis of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively, and induces adipocyte differentiation in NIH-PPARδ cells.

Product Specifications

CAS Number

[79558-09-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/L-165041.html

Purity

99.12

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(O)COC(C=C1)=CC=C1OCCCOC2=CC=C(C(C)=O)C(O)=C2CCC

Molecular Formula

C22H26O7

Molecular Weight

402.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Berger J, et al. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 1999 Mar 5;274 (10) :6718-25.|[2]Park, Jin-Hee., et al. The PPARδ ligand L-165041 inhibits vegf-induced angiogenesis, but the antiangiogenic effect is not related to PPARδ. Journal of Cellular Biochemistry (2012), 113 (6), 1947-1954.|[3]Lim, Hyun-Joung., et al. PPARδ ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR-/- mice. European Journal of Pharmacology (2009), 622 (1-3), 45-51.|[4]Lim, Hyun-Joung., et al. PPARδ agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle. Atherosclerosis (Amsterdam, Netherlands) (2009), 202 (2), 446-454.